In the presented results, “Panobinostat (LBH589)”, a novel HDAC inhibitor, has been shown to inhibit breast cancer progression by exosome-mediated suppression and demonstrate anti-tumor activity at lower concentrations (42, 43). Here, HDAC9 is linked to breast carcinoma.